TSH Receptor – Autoantibody Interactions

Abstract

TSH receptor (TSHR) autoantibodies (TRAbs) activate the TSHR cyclic AMP cascade (stimulating TRAbs) or act as TSHR antagonist (blocking TRAbs), and both types inhibit TSH binding to the TSHR. Isolation of human monoclonal TSHR autoantibodies (stimulating M22 and blocking 5C9) has been a key milestone in studies of the TSHR and TSHR autoimmunity. Comparison of M22 and TSH interactions with the TSHR at the atomic level reveal that M22 heavy and light chains mimic TSH α and β chains, respectively, in the way they bind to the receptor, but the evolutionary forces which have caused this close molecular mimicry are as yet completely unknown. More recently two more human monoclonal antibodies to the TSHR (K1-18 with stimulating and K1-70 with blocking activities) have been isolated from a single blood sample collected from a patient with hypothyroidism who previously presented with hyperthyroidism. K1-18 and K1-70 were derived from different lymphocytes as shown by V region genes analysis. This provides, for the first time, clear proof that a patient can produce both blocking and stimulating TRAbs at the same time. Although it has been postulated that stimulating and blocking TRAbs bind to different regions on the TSHR, our studies showed that antibodies of both types bind well to the TSHR containing only N-terminal amino acids 22–260. Whether TRAbs make contact with other parts of the TSHR in order to produce their biological effects (stimulation or blocking) remains to be elucidated.

Key words

Graves’ disease - TSH - TSH receptor antibodies - autoimmunity

References

• 1 Adams DD. Pathogenesis of the hyperthyroidism of Graves’ disease.  Br Med J. 1965;  1 1015-1019
• 2 Rees Smith B, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor.  Endocr Rev. 1988;  9 106-121
• 3 Rees Smith B, Sanders J, Furmaniak J. TSH receptor antibodies.  Thyroid. 2007;  17 923-938
• 4 Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies.  Endocr Rev. 1998;  19 673-716
• 5 Sanders J, Chirgadze DY, Sanders P, Baker S, Sullivan A, Bhardwaja A, Bolton J, Reeve M, Nakatake N, Evans M, Richards T, Powell M, Núñez Miguel R, Blundell TL, Furmaniak J, Rees Smith B. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody.  Thyroid. 2007;  17 395-410
• 6 Ando T, Latif R, Daniel S, Eguchi K, Davies TF. Dissecting linear and conformational epitopes on the native thyrotropin receptor.  Endocrinology. 2004;  145 5185-5193
• 7 Costagliola S, Bonomi M, Morgenthaler NG, Van Durme J, Panneels V, Refetoff S, Vassart G. Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity.  Mol Endocrinol. 2004;  18 3020-3034
• 8 Flynn JC, Gilbert JA, Meroueh C, Snower DP, David CS, Kong YM, Banga JP. Chronic exposure in vivo to thyrotropin receptor stimulating monoclonal antibodies sustains high thyroxine levels and thyroid hyperplasia in thyroid autoimmunity-prone HLA-DRB1*0301 transgenic mice.  Immunology. 2007;  122 261-267
• 9 Fox KM, Dias JA, van Roey P. Three-dimensional structure of human follicle-stimulating hormone.  Mol Endocrinol. 2001;  15 378-389
• 10 Fan QR, Hendrickson WA. Structure of human follicle-stimulating hormone in complex with its receptor.  Nature. 2005;  433 269-277
• 11 Núñez Miguel R, Sanders J, Chirgadze DY, Blundell TL, Furmaniak J, Rees Smith B. FSH and TSH binding to their respective receptors: similarities, differences and implication for glycoprotein hormone specificity.  J Mol Endocrinol. 2008;  41 145-164
• 12 Núñez Miguel R, Sanders J, Chirgadze DY, Furmaniak J, Rees Smith B. Thyroid stimulating autoantibody M22 mimics TSH binding to the TSH receptor leucine rich domain: a comparative structural study of protein-protein interactions.  J Mol Endocrinol. 2009;  42 381-395
• 13 Nakatake N, Sanders J, Richards T, Burne P, Barrett C, Pra CD, Presotto F, Betterle C, Furmaniak J, Rees Smith B. Estimation of serum TSH receptor autoantibody concentration and affinity.  Thyroid. 2006;  16 1077-1084
• 14 Sanders J, Bolton J, Sanders P, Jeffreys J, Nakatake N, Richards T, Evans M, Kiddie A, Summerhayes S, Roberts E, Núñez Miguel R, Furmaniak J, Rees Smith B. Effects of TSH receptor mutations on binding and biological activity of monoclonal antibodies and TSH.  Thyroid. 2006;  16 1195-1206
• 15 Sanders J, Evans M, Premawardhana LDKE, Depraetere H, Jeffreys J, Richards T, Furmaniak J, Rees Smith B. Human monoclonal thyroid stimulating autoantibody.  Lancet. 2003;  362 126-128
• 16 Sanders J, Jeffreys J, Depraetere H, Evans M, Richards T, Kiddie A, Brereton K, Premawardhana LD, Chirgadze DY, Núñez Miguel R, Blundell TL, Furmaniak J, Rees Smith B. Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function.  Thyroid. 2004;  14 560-570
• 17 Sanders J, Evans M, Betterle C, Sanders P, Bhardwaja A, Young S, Roberts E, Wilmot J, Richards T, Kiddie A, Small K, Platt H, Summerhayes S, Harris R, Reeve M, Coco G, Zanchetta R, Chen S, Furmaniak J, Rees Smith B. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.  Thyroid. 2008;  18 735-746
• 18 Jeffreys J, Depraetere H, Sanders J, Oda Y, Evans M, Kiddie A, Richards T, Furmaniak J, Rees Smith B. Characterization of the thyrotropin binding pocket.  Thyroid. 2002;  12 1051-1061
• 19 Flanagan JG, Cheng H-J. Alkaline phosphatase fusion proteins for molecular characterization and cloning of receptors and their ligands.  Meth Enzymol. 2000;  327 198-210
• 20 Brooking H, Ananieva-Jordanova R, Arnold C, Amoroso M, Powell M, Betterle C, Zanchetta R, Furmaniak J, Rees Smith B. A sensitive non-isotopic assay for GAD65 autoantibodies.  Clin Chim Acta. 2003;  331 55-59
• 21 Chen S, Willis J, Maclean C, Ananieva-Jordanova R, Amoroso MA, Brooking H, Powell M, Collins A, Bennett S, Mitchell S, Burne P, Furmaniak J, Rees Smith B. Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65.  Clin Chim Acta. 2005;  357 74-83
• 22 Loos U, Franz C, Minich WB, Büsselmann I. Direct assay of TSH receptor autoantibodies causing Graves’ disease correlates with the clinical diagnosis closer than assays based on TSH displacement.  Horm Res. 2007;  68 ((Suppl 3)) 21-91
• 23 Aalberse RC, Schuurman J. IgG4 breaking the rules.  Immunology. 2002;  105 9-19
• 24 van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JGJ, Aalberse RC, Parren PWHI. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.  Science. 2007;  317 1554-1557
• 25 Weetman AP, Byfield PGH, Black C, Reimer B. IgG heavy chain subclass restriction of thyrotropin binding inhibitory immunoglobulins in Graves’ disease.  Eur J Clin Invest. 1990;  20 406-410
• 26 Kraiem Z, Cho BY, Sadeh O, Shong MH, Pickerill P, Weetman AP. The IgG subclass distribution of TSH receptor blocking antibodies in primary hypothyroidism.  Clin Endocrinol. 1992;  37 135-140
• 27 Minich WB, Loos U. Detection of functionally different types of pathological autoantibodies against thyrotropin receptor in Graves’ patients sera by luminescent immunoprecipitation analysis.  Exp Clin Endocrinol Diabetes. 2000;  108 110-119
• 28 Minich WB, Lenzner C, Bergmann A, Morgenthaler NG. A coated tube assay for the detection of blocking thyrotropin receptor autoantibodies.  J Clin Endocrinol Metab. 2004;  89 352-356
• 29 Chazenbalk GD, Jaume JC, McLachlan SM, Rapoport B. Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves’ patients’ sera.  J Biol Chem. 1997;  272 18959-18965
• 30 Chazenbalk GD, Wang Y, Guo J, Hutchison JS, Segal D, Jaume JC, McLachlan SM, Rapoport B. A mouse monoclonal antibody to a thyrotropin receptor ectodomain variant provides insight into the exquisite antigenic conformational requirement, epitopes and in vivo concentration of human autoantibodies.  J Clin Endocrinol Metab. 1999;  84 702-710
• 31 Chazenbalk GD, McLachlan SM, Pichurin P, Yan XM, Rapoport B. A prion-like shift between two conformational forms of a recombinant thyrotropin receptor A-subunit module: purification and stabilization using chemical chaperones of the form reactive with Graves’ autoantibodies.  J Clin Endocrinol Metab. 2001;  86 1287-1293
• 32 Chazenbalk GD, Pichurin P, Chen CR, Latrofa F, Johnstone AP, McLachlan SM, Rapoport B. Thyroid-stimulating autoantibodies in Graves’ disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.  J Clin Invest. 2002;  110 209-217
• 33 Schwarz-Lauer L, Chazenbalk GD, McLachlan SM, Ochi Y, Nagayama Y, Rapoport B. Evidence for a simplified view of autoantibody interactions with the thyrotropin receptor.  Thyroid. 2002;  12 115-120
• 34 Da Costa CR, Johnstone AP. Production of the thyrotropin receptor extracellular domain as a glycosylphosphatidylinositol anchored membrane protein and its interaction with thyrotropin and autoantibodies.  J Biol Chem. 1998;  273 11874-11880
• 35 Cornelis S, Uttenweiler-Joseph S, Panneels V, Vassart G, Costagliola S. Purification and characterization of a soluble bioactive amino-terminal extracellular domain of the human thyrotropin receptor.  Biochemistry. 1998;  40 9860-9869
• 36 Osuga Y, Liang SG, Dallas JS, Wang C, Hsueh AJ. Soluble ecto-domain mutant of thyrotropin (TSH) receptor incapable of binding TSH neutralizes the action of thyroid-stimulating antibodies from Graves’ patients.  Endocrinology. 1998;  139 671-676
• 37 Szkudlinski WM, Teh NG, Grossmann M, Tropea JE, Weintraub BD. Engineering human glycoprotein hormone superactive analogues.  Nature Biotechnol. 1996;  14 1257-1263
• 38 Mueller S, Kleinau G, Jaeschke H, Paschke R, Krause G. Extended hormone binding site of the human TSHR: distinctive acidic residues in the hinge region are involved in bovine TSH binding and receptor activation.  J Biol Chem. 2008;  283 18048-18055
• 39 Mizutori U, Chen C-R, McLachlan SM, Rapoport B. The thyrotropin receptor hinge region is not simply a scaffold for the leucine-rich domain but contributes to ligand binding and signal transduction.  Mol Endocrinol. 2008;  22 1171-1182
• 40 Costagliola S, Panneels V, Bonomi M, Koch J, Many MC, Smits G, Vassart G. Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors.  EMBO J. 2002;  21 504-513
• 41 Gallivan JP, Dougherty DA. Cation-π interactions in structural biology.  Proc Natl Acad Sci USA. 1999;  96 9459-9464

Correspondence